Citation
Seki, K, et al. "Diagnosis of Pancreatic Adenocarcinoma By Detection of Human Telomerase Reverse Transcriptase Messenger RNA in Pancreatic Juice With Sample Qualification." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 7, no. 7, 2001, pp. 1976-81.
Seki K, Suda T, Aoyagi Y, et al. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res. 2001;7(7):1976-81.
Seki, K., Suda, T., Aoyagi, Y., Sugawara, S., Natsui, M., Motoyama, H., Shirai, Y., Sekine, T., Kawai, H., Mita, Y., Waguri, N., Kuroiwa, T., Igarashi, M., & Asakura, H. (2001). Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 7(7), 1976-81.
Seki K, et al. Diagnosis of Pancreatic Adenocarcinoma By Detection of Human Telomerase Reverse Transcriptase Messenger RNA in Pancreatic Juice With Sample Qualification. Clin Cancer Res. 2001;7(7):1976-81. PubMed PMID: 11448913.
TY - JOUR
T1 - Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification.
AU - Seki,K,
AU - Suda,T,
AU - Aoyagi,Y,
AU - Sugawara,S,
AU - Natsui,M,
AU - Motoyama,H,
AU - Shirai,Y,
AU - Sekine,T,
AU - Kawai,H,
AU - Mita,Y,
AU - Waguri,N,
AU - Kuroiwa,T,
AU - Igarashi,M,
AU - Asakura,H,
PY - 2001/7/13/pubmed
PY - 2001/10/26/medline
PY - 2001/7/13/entrez
SP - 1976
EP - 81
JF - Clinical cancer research : an official journal of the American Association for Cancer Research
JO - Clin Cancer Res
VL - 7
IS - 7
N2 - PURPOSE: We evaluated the diagnostic efficacy of detection of human telomerase reverse transcriptase (hTERT) message, a catalytic domain of human telomerase, in endoscopic retrograde pancreatography (ERP)-derived pancreatic juice. EXPERIMENTAL DESIGN: Both hTERT and CD25 expression were detected by reverse transcription-PCR (RT-PCR) in 17 patients with pancreatic adenocarcinoma (PC), 12 patients with chronic pancreatitis (CP), and 7 patients with no ERP abnormality (N). In the same patients, beta-actin message was semiquantified by competitive RT-PCR. K-ras codon 12 mutations were concomitantly analyzed by enriched PCR-SSCP in 11 and 7 PC and CP cases, respectively. RESULTS: Expression of hTERT was detected in 88% of PC cases and 17% of CP cases but not in the normal control (N). Alterations in K-ras were detected in 73% of PC cases and 57% of CP cases, respectively. beta-Actin mRNA was expressed in >3.0 x 10(1) copies/microl in all but two PC cases in which hTERT mRNA was not detected. CD25-positive and -negative peripheral lymphocytes were isolated from a normal volunteer using a fluorescent activating cell sorter. The hTERT message was detected in CD25-positive peripheral lymphocytes and in 18, 25, and 0% of the pancreatic juice samples from PC, CP, and N cases, respectively. All CP cases expressing hTERT message were also CD25 positive. CONCLUSIONS: These results suggest that detection of hTERT mRNA in pancreatic juice is a powerful tool to discriminate PC from CP, particularly when the samples are qualified against beta-actin mRNA levels and contaminating CD25-positive lymphocytes.
SN - 1078-0432
UR - https://www.unboundmedicine.com/medline/citation/11448913/Diagnosis_of_pancreatic_adenocarcinoma_by_detection_of_human_telomerase_reverse_transcriptase_messenger_RNA_in_pancreatic_juice_with_sample_qualification_
L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=11448913
DB - PRIME
DP - Unbound Medicine
ER -